AsthmaNCT07351916
Remission in Adults With Mild-to-moderate Asthma in Thailand
An observational study of Asthma and Mild-to-moderate Asthma, run by Thammasat University at 2 sites in Thailand.
Trial summary
The goal of this observational study is to determine the prevalence of remission among adults with mild-to-moderate asthma, as well as the factors associated with remission in Thailand. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Asthma, Mild-to-moderate Asthma, Asthma Control Level
- What is being tested?
- Spirometry, Fractional exhaled nitric oxide (FeNO) test and Blood eosinophil count (BEC)
- How many people
- 289 participants
- Where
- 2 sitesThailand
- Study dates
- 1 Feb 2026to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Thai patients aged 18 years or older with mild-to-moderate asthma are included in the study
Who may be able to join
- mild-to-moderate asthma
- age 18 years or older
Who cannot join
- inability to perform spirometry or fractional exhaled nitric oxide (FeNO) test
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Thailand2 sites, 2 recruiting
- Recruiting
Narongkorn Saiphoklang
Pathum Thani, Changwat Pathum Thani, 12120
Narongkorn Saiphoklang, MD, +6629269794, M_narongkorn@hotmail.com
Sirashat Hanvivattanakul, MD, +6629269794, boss32_@hotmail.com
- Recruiting
Faculty of Medicine, Thammasat University
Pathum Thani, 12120
Narongkorn Saiphoklang, MD, 029269794, M_narongkorn@hotmail.com
Sirashat Hanvivattanakul, MD, +6629269701, boss32_@hotmail.com
About this study
The goal of this observational study is to determine the prevalence of remission among adults with mild-to-moderate asthma, as well as the factors associated with remission in Thailand.
The main question the study aims to answer is:
What is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete a questionnaire on asthma symptoms and undergo pulmonary function testing and a blood test once.
Read the detailed description
This study is a cross-sectional study. Thai patients aged 18 years or older with mild-to-moderate asthma are included in the study. Participants will complete two questionnaires about asthma control: the Global Initiative for Asthma (GINA) and the Asthma Control Test (ACT), and will perform spirometry, a fractional exhaled nitric oxide (FeNO) test, and blood eosinophil counts (BEC).
GINA and ACT are questionnaires used to assess the level of asthma control.
- Conditions
- Asthma, Mild-to-moderate Asthma, Asthma Control Level
- Being tested
- Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires, Spirometry, Fractional exhaled nitric oxide (FeNO) test, Blood eosinophil count (BEC)
- Keywords
- asthma, asthma control, mild-to-moderate asthma, Thailand, remission, FeNO, blood eosinophil count
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnairesOther
GINA and ACT are questionnaires used to assess the level of asthma control.
SpirometryOther
Spirometry is a tool used to assess pulmonary function.
Fractional exhaled nitric oxide (FeNO) testOther
FeNO is a tool used to assess eosinophilic airway inflammation and asthma remission.
Blood eosinophil count (BEC)Other
BEC is a tool used to assess eosinophilic inflammation and asthma remission.
| Study group | Role | What they receive |
|---|---|---|
| Mild-to-moderate asthma | Patients aged 18 years or older with mild-to-moderate asthma. Mild asthma refers to asthma patients who experience symptoms <3 times per week, have preserved lung function (FEV₁ or PEF >80% of predicted), and whose symptoms can be adequately controlled with low-dose inhaled corticosteroids (low-dose ICS) alone, without the need for long-acting bronchodilators or other controller medications.
Moderate asthma refers to asthma patients who have symptoms >4-5 days per week or experience nocturnal asthma symptoms >1 per week, and who require treatment with medium-dose inhaled corticosteroids (medium-dose ICS) or low-dose ICS in combination with a long-acting β₂-agonist (low-dose ICS/LABA) to achieve symptom control and prevent exacerbations. Receives: Other: Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires; Other: Spirometry; Other: Fractional exhaled nitric oxide (FeNO) test; Other: Blood eosinophil count (BEC) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence rate of mild-to-moderate asthma remission
Prevalence rate of mild-to-moderate asthma remission (%)
Measured: An average of 1 year
Secondary outcomes (5)
Asthma control in patients with mild-to-moderate asthma
Rate of patients with well-controlled asthma. Well-controlled asthma is defined as an Asthma Control Test (ACT) score of 20 or higher.
Measured: At baseline and at 12 months
Airway obstruction in patients with mild-to-moderate asthma
Airway obstruction is assessed using FEV1/FVC ratio on spirometry.
Measured: At baseline and at 12 months
Severity of aiway obstruction in patients with mild-to-moderate asthma
The severity of aiway obstruction is assessed using FEV1 % predicted on spirometry.
Measured: At baseline and at 12 months
Eosinophil airway inflammation in patients with mild-to-moderate asthma
Eosinophil airway inflammation is assessed using blood eosinophil count (cells/µL).
Measured: At baseline and at 12 months
Type 2 airway inflammation in patients with mild-to-moderate asthma
Type 2 airway inflammation is assessed using fractional exhaled nitric oxide (FeNO, ppb).
Measured: At baseline and at 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jan 2026
- Study start1 Feb 2026
- Primary completion31 Oct 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for AsthmaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 289 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Thammasat University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Narongkorn Saiphoklang, MD, Thammasat University
- Investigators
- Narongkorn Saiphoklang, MD, Principal investigator, Thammasat University Faculty of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07351916
- Sponsor's protocol ID
- MTU-EC-IM-0-282/68
- Status last verified
- Apr 2026
- First submitted
- 10 Jan 2026
- Last updated
- 17 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD and documents will be available for sharing immediately after publication for a period of 2 years.
Publications
Ishizuka M, Sugimoto N, Kobayashi K, Takeshita Y, Imoto S, Koizumi Y, Togashi Y, Tanaka Y, Nagata M, Hattori S, Uehara Y, Suzuki Y, Toyota H, Ishii S, Nagase H. Clinical remission of mild-to-moderate asthma: Rates, contributing factors, and stability. J Allergy Clin Immunol Glob. 2025 Jan 30;4(2):100431. doi: 10.1016/j.jacig.2025.100431. eCollection 2025 May.
PubMed 40091885Holm M, Omenaas E, Gislason T, Svanes C, Jogi R, Norrman E, Janson C, Toren K; RHINE Study Group. Remission of asthma: a prospective longitudinal study from northern Europe (RHINE study). Eur Respir J. 2007 Jul;30(1):62-5. doi: 10.1183/09031936.00121705. Epub 2007 Mar 14.
PubMed 17360725Tupper OD, Hakansson KEJ, Ulrik CS. Remission and Changes in Severity Over 30 Years in an Adult Asthma Cohort. J Allergy Clin Immunol Pract. 2021 Apr;9(4):1595-1603.e5. doi: 10.1016/j.jaip.2020.11.013. Epub 2020 Nov 19.
PubMed 33220516Chiewchalermsri C, Kanjanawasee D, Saiphoklang N, Chirakalwasan N, Sriprasart T, Senavonge A, Sanguanwong N, Kamalaporn H, Athipongarporn A, Hachai S, Boonsawat W, Brannan JD, Song WJ, Ruxrungtham K, Poachanukoon O. Asthma remission: A path to cure? Asian Pac J Allergy Immunol. 2025 Jun;43(2):135-150. doi: 10.12932/AP-240525-2082.
PubMed 40652405
Study at a glance
From the registry record, last updated by the sponsor on 17 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Remission in Adults With Mild-to-moderate Asthma in Thailand
- ClinicalTrials.gov ID
- NCT07351916
- Acronym / sponsor ID
- MTU-EC-IM-0-282/68
- Conditions
- Asthma, Mild-to-moderate Asthma, Asthma Control Level
- Keywords
- asthma, asthma control, mild-to-moderate asthma, Thailand, remission, FeNO, blood eosinophil count
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 289 participants (estimated)
- Lead sponsor
- Thammasat UniversityUniversity, hospital or other
- Study start
- 1 Feb 2026 (actual)
- Primary completion
- 31 Oct 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 20 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to determine the prevalence of remission among adults with mild-to-moderate asthma, as well as the factors associated with remission in Thailand.
The main question the study aims to answer is:
What is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete a questionnaire on asthma symptoms and undergo pulmonary function testing and a blood test once.
Detailed description
This study is a cross-sectional study. Thai patients aged 18 years or older with mild-to-moderate asthma are included in the study. Participants will complete two questionnaires about asthma control: the Global Initiative for Asthma (GINA) and the Asthma Control Test (ACT), and will perform spirometry, a fractional exhaled nitric oxide (FeNO) test, and blood eosinophil counts (BEC).
GINA and ACT are questionnaires used to assess the level of asthma control.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Mild-to-moderate asthma | – | Other: Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires, Other: Spirometry, Other: Fractional exhaled nitric oxide (FeNO) test, Other: Blood eosinophil count (BEC)Patients aged 18 years or older with mild-to-moderate asthma. Mild asthma refers to asthma patients who experience symptoms <3 times per week, have preserved lung function (FEV₁ or PEF >80% of predicted), and whose symptoms can be adequately controlled with low-dose inhaled corticosteroids (low-dose ICS) alone, without the need for long-acting bronchodilators or other controller medications. Moderate asthma refers to asthma patients who have symptoms >4-5 days per week or experience nocturnal asthma symptoms >1 per week, and who require treatment with medium-dose inhaled corticosteroids (medium-dose ICS) or low-dose ICS in combination with a long-acting β₂-agonist (low-dose ICS/LABA) to achieve symptom control and prevent exacerbations. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Thai patients aged 18 years or older with mild-to-moderate asthma are included in the study
Key inclusion criteria (2 listed)
- mild-to-moderate asthma
- age 18 years or older
Key exclusion criteria (1 listed)
- inability to perform spirometry or fractional exhaled nitric oxide (FeNO) test
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnairesGINA and ACT are questionnaires used to assess the level of asthma control. | Other | Mild-to-moderate asthma |
| SpirometrySpirometry is a tool used to assess pulmonary function. | Other | Mild-to-moderate asthma |
| Fractional exhaled nitric oxide (FeNO) testFeNO is a tool used to assess eosinophilic airway inflammation and asthma remission. | Other | Mild-to-moderate asthma |
| Blood eosinophil count (BEC)BEC is a tool used to assess eosinophilic inflammation and asthma remission. | Other | Mild-to-moderate asthma |
Primary outcome
Prevalence rate of mild-to-moderate asthma remission
Time frame: An average of 1 year
Prevalence rate of mild-to-moderate asthma remission (%)
5 secondary outcomes
Asthma control in patients with mild-to-moderate asthma
Time frame: At baseline and at 12 months
Airway obstruction in patients with mild-to-moderate asthma
Time frame: At baseline and at 12 months
Severity of aiway obstruction in patients with mild-to-moderate asthma
Time frame: At baseline and at 12 months
Eosinophil airway inflammation in patients with mild-to-moderate asthma
Time frame: At baseline and at 12 months
Type 2 airway inflammation in patients with mild-to-moderate asthma
Time frame: At baseline and at 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Apr 2026.
- Results publication: PubMed 40091885Ishizuka M, Sugimoto N, Kobayashi K, Takeshita Y, Imoto S, Koizumi Y, Togashi Y, Tanaka Y, Nagata M, Hattori S, Uehara Y, Suzuki Y, Toyota H, Ishii S, Nagase H. Clinical remission of mild-to-moderate asthma: Rates, contributing factors, and stability. J Allergy Clin Immunol Glob. 2025 Jan 30;4(2):100431. doi: 10.1016/j.jacig.2025.100431. eCollection 2025 May.
- Results publication: PubMed 17360725Holm M, Omenaas E, Gislason T, Svanes C, Jogi R, Norrman E, Janson C, Toren K; RHINE Study Group. Remission of asthma: a prospective longitudinal study from northern Europe (RHINE study). Eur Respir J. 2007 Jul;30(1):62-5. doi: 10.1183/09031936.00121705. Epub 2007 Mar 14.
- Results publication: PubMed 33220516Tupper OD, Hakansson KEJ, Ulrik CS. Remission and Changes in Severity Over 30 Years in an Adult Asthma Cohort. J Allergy Clin Immunol Pract. 2021 Apr;9(4):1595-1603.e5. doi: 10.1016/j.jaip.2020.11.013. Epub 2020 Nov 19.
- Results publication: PubMed 40652405Chiewchalermsri C, Kanjanawasee D, Saiphoklang N, Chirakalwasan N, Sriprasart T, Senavonge A, Sanguanwong N, Kamalaporn H, Athipongarporn A, Hachai S, Boonsawat W, Brannan JD, Song WJ, Ruxrungtham K, Poachanukoon O. Asthma remission: A path to cure? Asian Pac J Allergy Immunol. 2025 Jun;43(2):135-150. doi: 10.12932/AP-240525-2082.
- Individual participant dataSharing planned: Yes. IPD and documents will be available for sharing immediately after publication for a period of 2 years.
Related trials for Asthma
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 1
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
Asthma, Mild Asthma
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Narongkorn Saiphoklang, MD principal investigator
Thammasat University Faculty of Medicine
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Asthma and Mild-to-moderate Asthma, run by Thammasat University at 2 sites in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Narongkorn Saiphoklang, MD (+6629269794, M_narongkorn@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence rate of mild-to-moderate asthma remission (time frame: An average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07351916, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2026.